Could a common diabetes drug shield hearts from AF-Related failure?
NCT ID NCT07482020
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether empagliflozin, a diabetes drug, can improve left atrial function in 66 people with paroxysmal atrial fibrillation, high blood pressure, and abnormal glucose metabolism. The goal is to see if it can prevent heart failure. Participants will be randomly assigned to receive the drug or a placebo, and heart function will be measured using advanced imaging.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
empagliflozin (an SGLT2 inhibitor)
What this could lead to
If it works, this could point toward a new way to prevent heart failure in people with atrial fibrillation and related metabolic problems.
What could go wrong
This is a small, early-phase trial (66 people) testing a surrogate marker, not hard outcomes. The drug may not improve heart function or prevent heart failure in real-world settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Affiliated Huashan Hospital, Cardiology Department
RECRUITINGShanghai, Shanghai Municipality, 200036, China
Contact Phone: •••-•••-•••• Email: •••••@•••••